

# INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

## MEETING MINUTES

**Meeting Date:** Wednesday, October 22, 2025  
**Time:** 3:00 pm Eastern Time  
**Location:** Zoom Teleconference  
**Institution:** UCONN Health, Farmington, CT  
**Principal Investigator:** Rebecca Riba-Wolman, MD  
**Protocol:** Beam Therapeutics, **BTX-301-001**  
**NCT Number:** NCT06735755  
**Meeting Type:** Continuing Review of Protocol and Site  
**Title:** A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients with Glycogen Storage Disease Type Ia (GSDIa) Homozygous or Compound Heterozygous for the G6PC1 c.247C>T (p.R83C) Variant

### 1. Call to order:

The Meeting was called to order at 3:14 pm Eastern Time.

### 2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

### 3. Declaration of quorum:

Four voting members were present, including one local member unaffiliated with the institution. Also present were four Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

### 4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

### 5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

### 6. Approval of previous meeting minutes:

Minutes Approved - YES: 4 NO: 0 ABSTAIN: 0

### 7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair provided an overview of changes since the last review.

### 8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices are required for BEAM-301** since it consists of a gene editing product administered directly to subjects which can permanently modify the cellular genome within the body. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of BEAM-301 locally**, provided that other biosafety criteria for study closure are also met. The Committee reaffirmed this determination.

### 9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 4

NO: 0

ABSTAIN: 0

## INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

### **10. Review of proposed facilities and practices:**

The Chair provided an overview of the arrangement for the facilities and practices.

#### **Points of Discussion:**

1. The Committee recommended that the non-safety needle not be recapped and instead be immediately discarded into a sharps container and that Section 3.3 of the Biosafety SOP be revised accordingly.
2. An Institutional Representative confirmed that all Biological Safety Cabinets (BSCs) are recertified on a semi-annual basis. The Committee recommended that the most recent BSC certifications for the [REDACTED] be submitted to IBC Services.
3. The Committee recommended that a photo of the eye screen attached to the surgical mask be submitted to IBC Services.
4. The Committee recommended that Site Inspection Checklist (#11) be revised to select "BSC" as the type of equipment used.
5. The Committee noted that IATA Shipping Training for staff members expires two years after completion of training, not three years after training as noted on the Certification documents.
6. An Institutional Representative confirmed that the [REDACTED] dosing area has a plumbed eyewash station located in a separate room across the hallway from the dosing rooms, separated by two closeable doors. The Committee recommended that prefilled disposable eyewash bottles be made available in these rooms during subject dosing.

### **11. Site requirements:**

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

### **12. Vote on the Site:**

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 4

NO: 0

ABSTAIN: 0

### **13. Advice to the Institution:** None.

### **14. Meeting adjourned:** The meeting was adjourned at 3:28 pm Eastern Time.